TradingMenu expanded
Forge Markets Browse Companies
DataMenu expanded
Forge Data Private Market Index IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies In Europe
InsightsMenu expanded
All Insights Blog Glossary Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Updates Forge Investment Outlook Startup News
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Browse Companies
Data Menu expandedData
Forge Data
Private Market Index
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
In Europe
Insights Menu expandedInsights
All Insights
Blog
Glossary
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Updates
Forge Investment Outlook
Startup News
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Private Companies / Unlearn Stock

Unlearn Stock

unlearn.aiHealthcare / BioTech & PharmaFounded: 2017Funding to Date: $85.17MM

Unlearn.AI is an AI healthcare company specializing in creating digital twins of patients to conduct clinical studies. Their technology aims to estimate the effects of therapy options for those affected by disease. Unlearn.AI was founded in 2017 by Charles Fisher Ph.D., Jonathan Walsh Ph.D., Aaron Smith Ph.D., and Graham Siegel JD and is headquartered in San Francisco, CA.

Buy or sell Unlearn stockLearn more about Unlearn IPO

Register To Buy and Sell Shares

For more details on financing and valuation for Unlearn, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Unlearn’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Unlearn.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Unlearn investors also invested in these private companies

8VC
Alumni Ventures
DCVC
Mubadala Capital Ventures
EPIC Ventures

Team

Management Team

Charles Fisher Ph.D
Co-Founder, Chief Executive Officer, President & Board Member
Dave Miller
Chief Science Officer
Jonathan Walsh Ph.D
Co-Founder & Head of Data Science
Aaron Smith Ph.D
Co-Founder, Head of Machine Learning & Board Member

Board Members

Alaa Halawa
Mubadala Capital-Ventures
Dylan Morris Ph.D
Insight Partners
Francisco Gimenez Ph.D
8VC
John Hamer Ph.D
DCVC

Frequently Asked Questions About Unlearn’s Stock

plusminus
Can you buy Unlearn stock?
Unlearn is not publicly traded on NYSE or NASDAQ in the U.S. To buy Unlearn stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Unlearn stock?
Yes, you can sell stock of a private company like Unlearn. Forge can help you sell your Unlearn stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Unlearn’s stock price?
Unlearn is a privately held company and therefore does not have a public stock price. However, you may access Unlearn’s private market stock price with Forge Data.
plusminus
What is Unlearn’s stock ticker symbol?
Unlearn does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Other companies like Unlearn in the BioTech & Pharma sector

Colossal Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.01B

Altos Labs

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$3.67B

Tempus

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$8.7B

AI Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$110MM

Atomwise

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$405.17MM

Mammoth Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.08B

Biosplice Therapeutics

Sector
Healthcare / BioTech & Pharma
 
 

Ginkgo Bioworks

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$4.89B

Caris Life Sciences

Sector
Healthcare / BioTech & Pharma
 
 

News Highlights

Reuters 03/21/2023
Biotech AI startup Unlearn adds $15 mln and OpenAI CTO to board
Unlearn.AI, which has built a machine learning platform that creates "digital twin" profiles of patients in clinical trials, has raised $15 million to expand partnerships and accelerate regulatory approval, the company told Reuters on Tuesday.
The Wall Street Journal 01/01/2023
A Perk to Getting These Jobs: You Pick Your Pay
Unlearn, which uses artificial intelligence to speed clinical trials, recently began offering new hires multiple pay options. It’s among a growing number of companies that let new hires customize their compensation with different combinations of salary, equity and, in some cases, benefits.
Fast Company 11/28/2022
How ‘digital twins’ could change the way we develop new drugs
Now, using machine learning and generative AI, a startup called Unlearn.ai is aiming to transform clinical trials by tackling one of its biggest challenges: recruiting enough people to participate. Its solution? Digital twins.

Trending Companies

Frequently Asked Questions

Updated on: Dec 1, 2023

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.